ALS(筋萎縮性側索硬化症)に負けないで
全世界から最新の治療情報を見つけ出し、ここで紹介します。完治するまで戦い続けましょう!
201709<<12345678910111213141516171819202122232425262728293031>>201711
Yoo会長がアメリカの大学で共同研究(University of Minnesota Medical Center)
Yoo会長がアメリカの大学で共同研究、すぐ始まるアメリカでの臨床試験についての書類です。日本より早くFDAの許可が出るかも。

We have also been studying the use of UDCA and TUDCA in treating animal models of ischemic and hemorrhagic stroke, ischemic heart injury, retinitis pigmentose, Huntington disease, and Parkinson disease, among others. In addition, we recently published a report regarding the penetration of UDCA into the cerebrospinal fluid of patients with ALS. Although we have yet to report on the functional benefits of UDCA in these patients we are observing a stabilization in the condition of these ALS patients in support of your clinical trial in South Korea.
We would like to extend to you an invitation to come and visit the University of Minnesota Medical School, talk about your work and discuss the possibility of a formal collaboration. We feel that such an association would be mutually beneficial and more rapidly advance the use of UDCA in treating patients with progressively degenerative conditions, in addition to more acute disorders such as myocardial infarction or stroke.

ネオユース社のブログ
http://blog.naver.com/neoyouth1/10090324452
スポンサーサイト
コメント
コメント
コメントの投稿

管理者にだけ表示を許可する
トラックバック
トラックバック URL
トラックバック
copyright © 2017 Powered By FC2ブログ allrights reserved.